Bob Kronemyer

8900 N KENDALL DR

Freelance writer for Contemporary OB/GYN

Articles

Relugolix for treating uterine fibroids

January 19, 2022

A phase 2, multicenter study has found relugolix (Myfembree; Myovant Sciences) significantly decreases menstrual blood loss in women with uterine leiomyomas and is mostly well tolerated.Relugolix is a small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist.

Microbial interplay of recurrent vulvovaginal candidiasis pathobiology

January 19, 2022

A clinical study has confirmed that the pathophysiology of recurrent vulvovaginal candidiasis (RVVC) relies primarily on Candida albicans (C. albicans)-specific attributes like hyphal morphogenesis, biofilm formation and pathogenesis that differentiate it from other prominent non-albicans C. (NAC) species.

Infiltrative endometriosis without endometrioma

January 18, 2022

A case report of infiltrative endometriosis without endometrioma underscores the need to consider endometriosis in the differential for patients with pelvic masses and to recognize possible features that might indicate the diagnosis.

Patient perspectives on vulvovaginal candidiasis

January 18, 2022

Among women with vulvovaginal candidiasis (VVC) or recurrent VVC (RVVC), the 3 most common signs and symptoms are itching (91.2%), burning (68.3%), and redness (58.1%), according to an online patient survey in BMC Womens Health.